G. Dwivedi, S. Hallihosur, and L. Rangan, Evergreening: A deceptive device in patent rights, Technology in Society, vol.32, issue.4, pp.324-330, 2010.
DOI : 10.1016/j.techsoc.2010.10.009

I. Bansal, S. Deeptymaya, G. Bakshi, and S. Singh, Evergreening -a controversial issue in pharma milieu, J Intell Prop Rights, vol.14, pp.299-306, 2009.

A. Wertheimer and T. Santella, Pharmacoevolution: the advantages of incremental innovation. IPN Working Papers on Intellectural Property, Innovation and Health International Policy Network, 2009.

B. Whitehead and K. Stuart, Managing generic competition and patent strategies in the pharmaceutical industry, Journal of Intellectual Property Law & Practice, vol.3, issue.4, pp.226-235, 2008.
DOI : 10.1093/jiplp/jpn013

M. Hutchins, Extending the monopoly ??? How 'secondary patents' can be used to delay or prevent generic competition upon expiry of the basic product patent, Journal of Generic Medicines, vol.1, issue.1, pp.57-71, 2003.
DOI : 10.1057/palgrave.jgm.4940018

C. Hemphill and B. Sampat, Evergreening, patent challenges, and effective market life in pharmaceuticals, Journal of Health Economics, vol.31, issue.2, pp.327-339, 2012.
DOI : 10.1016/j.jhealeco.2012.01.004

T. Faunce and J. Lexchin, Linkage' pharmaceutical evergreening in Canada and Australia. Aust New Zealand Health Policy, 2007.

D. Hughes, Less is More: Medicines that Require Less Frequent Administration Improve Adherence, but Are They Better?, PharmacoEconomics, vol.33, issue.3, pp.211-213, 2006.
DOI : 10.2165/00019053-200624030-00001

K. Gaudry, Evergreening: a common practice to protect new drugs, Nature Biotechnology, vol.29, issue.10, pp.876-878, 2011.
DOI : 10.1377/hlthaff.20.5.216

D. Hughes and R. Ferner, New drugs for old: disinvestment and NICE, BMJ, vol.340, issue.feb25 1, p.572, 2010.
DOI : 10.1136/bmj.c572
URL : http://www.bmj.com/cgi/content/short/340/feb25_1/c572

P. Kubler, New drugs for old, Australian Prescriber, vol.29, issue.6, pp.148-149, 2006.
DOI : 10.18773/austprescr.2006.088

G. Tucker, Chiral switches, The Lancet, vol.355, issue.9209, pp.1085-1087, 2000.
DOI : 10.1016/S0140-6736(00)02047-X

S. Svensson and P. Mansfield, Escitalopram: superior to citalopram or a chiral chimera? Psychother Psychosom, pp.10-16, 2004.

O. Dyer, Lundbeck broke advertising rules, BMJ, vol.326, issue.7397, p.1004, 2003.
DOI : 10.1136/bmj.326.7397.1004
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1125924

V. Smith, D. Devane, C. Begley, and M. Clarke, Methodology in conducting a systematic review of systematic reviews of healthcare interventions, BMC Medical Research Methodology, vol.156, issue.10, p.15, 2011.
DOI : 10.1111/j.1479-828X.2007.00759.x

G. Gartlehner, B. Gaynes, R. Hansen, P. Thieda, A. Deveaugh-geiss et al., Comparative Benefits and Harms of Second-Generation Antidepressants: Background Paper for the American College of Physicians, Annals of Internal Medicine, vol.149, issue.10, pp.734-750, 2008.
DOI : 10.7326/0003-4819-149-10-200811180-00008

A. Cipriani, T. Furukawa, G. Salanti, J. Geddes, J. Higgins et al., Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis, The Lancet, vol.373, issue.9665, pp.746-758, 2009.
DOI : 10.1016/S0140-6736(09)60046-5

E. Turner, A. Matthews, E. Linardatos, R. Tell, and R. Rosenthal, Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy, New England Journal of Medicine, vol.358, issue.3, pp.252-260, 2008.
DOI : 10.1056/NEJMsa065779

H. Bucher, G. Guyatt, L. Griffith, and S. Walter, The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials, Journal of Clinical Epidemiology, vol.50, issue.6, pp.683-691, 1997.
DOI : 10.1016/S0895-4356(97)00049-8

R. Riley, J. Higgins, and J. Deeks, Interpretation of random effects meta-analyses, BMJ, vol.342, issue.feb10 2, p.549, 2011.
DOI : 10.1136/bmj.d549

F. Song, Y. Loke, T. Walsh, A. Glenny, A. Eastwood et al., Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews, BMJ, vol.338, issue.apr03 1, p.1147, 2009.
DOI : 10.1136/bmj.b1147

F. Song, D. Altman, A. Glenny, and J. Deeks, Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses, BMJ, vol.326, issue.7387, p.472, 2003.
DOI : 10.1136/bmj.326.7387.472

J. Peters, A. Sutton, D. Jones, K. Abrams, and L. Rushton, Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry, Journal of Clinical Epidemiology, vol.61, issue.10, pp.991-996, 2008.
DOI : 10.1016/j.jclinepi.2007.11.010

P. Tuppin, L. De-roquefeuil, A. Weill, P. Ricordeau, and Y. Merlière, French national health insurance information system and the permanent beneficiaries sample, Revue d'??pid??miologie et de Sant?? Publique, vol.58, issue.4, pp.286-290, 2010.
DOI : 10.1016/j.respe.2010.04.005

L. De-roquefeuil, A. Studer, A. Neumann, and Y. Merlière, L'??chantillon g??n??raliste de b??n??ficiaires??: repr??sentativit??, port??e et limites, Pratiques et Organisation des Soins, vol.40, issue.3, pp.213-223, 2009.
DOI : 10.3917/pos.403.0213

J. Ou, G. Xun, R. Wu, L. Li, M. Fang et al., Efficacy and safety of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, randomized, double-blind, flexible-dose study, Psychopharmacology, vol.29, issue.2-3, pp.639-646, 2011.
DOI : 10.1007/s00213-010-1822-y

D. Lathyris, N. Patsopoulos, G. Salanti, and J. Ioannidis, Industry sponsorship and selection of comparators in randomized clinical trials, European Journal of Clinical Investigation, vol.59, issue.2, pp.172-182, 2010.
DOI : 10.1111/j.1365-2362.2009.02240.x

J. Lexchin, L. Bero, B. Djulbegovic, and O. Clark, Pharmaceutical industry sponsorship and research outcome and quality: systematic review, BMJ, vol.326, issue.7400, pp.1167-1170, 2003.
DOI : 10.1136/bmj.326.7400.1167
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC156458

L. Bero, F. Oostvogel, P. Bacchetti, and K. Lee, Factors Associated with Findings of Published Trials of Drug???Drug Comparisons: Why Some Statins Appear More Efficacious than Others, PLoS Medicine, vol.325, issue.6, p.184, 2007.
DOI : 10.1371/journal.pmed.0040184.st003

I. Chalmers and R. Matthews, What are the implications of optimism bias in clinical research? Lancet, pp.449-450, 2006.

G. Salanti, S. Dias, N. Welton, A. Ades, V. Golfinopoulos et al., Evaluating novel agent effects in multiple-treatments metaregression, pp.2369-2383, 2010.

M. Newman and O. Wright, NHS pays millions of pounds more than it needs to for drugs. The Independent, 2011.

J. Ioannidis, Effectiveness of antidepressants: an evidence myth constructed from a thousand randomized trials? Philos Ethics Humanit Med, p.14, 2008.

E. Mills, I. Ghement, C. O-'regan, and K. Thorlund, Estimating the Power of Indirect Comparisons: A Simulation Study, PLoS ONE, vol.370, issue.1, p.16237, 2011.
DOI : 10.1371/journal.pone.0016237.t009

S. Heres, J. Davis, K. Maino, E. Jetzinger, W. Kissling et al., Why Olanzapine Beats Risperidone, Risperidone Beats Quetiapine, and Quetiapine Beats Olanzapine: An Exploratory Analysis of Head-to-Head Comparison Studies of Second-Generation Antipsychotics, American Journal of Psychiatry, vol.163, issue.2, pp.185-194, 2006.
DOI : 10.1176/appi.ajp.163.2.185

. Hoyle, Future Drug Prices and Cost-Effectiveness Analyses, PharmacoEconomics, vol.326, issue.7, pp.589-602, 2008.
DOI : 10.2165/00019053-200826070-00006

. Alkhafaji, Impact of evergreening on patients and health insurance: a meta analysis and reimbursement cost analysis of citalopram/escitalopram antidepressants, BMC Medicine, vol.26, issue.1, p.142, 2012.
DOI : 10.2165/00019053-200826070-00006
URL : https://hal.archives-ouvertes.fr/inserm-00764321